Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat
Liver International · 2024
DOI: 10.1111/liv.15982 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Liver International, 2024. Verfasst von Eleni Karatza und 8 weiteren Autor:innen. Beteiligte Einrichtung: The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Pruritus, Liver Cirrhosis, Biliary, Bile Acids and Salts. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Background & Aims Total serum bile acid (TSBA) levels are elevated in patients with primary biliary cholangitis (PBC) and may mediate cholestatic pruritus. Linerixibat, an ileal bile acid transporter inhibitor, improved pruritus in patients with PBC. We explored the relationship between linerixibat dose, TSBA concentration, and pruritus.
Methods
Data from Phase 1/2 trials were used to develop a population kinetic‐pharmacodynamic model to characterize the linerixibat dose–TSBA relationship. Individual Bayesian parameter estimates for participants in the GLIMMER study were used to derive the area under the TSBA concentration curve over 24 h (AUC 0–24 ). Time‐matched post hoc estimates of AUC 0–24 were correlated with pruritus reported on a 0–10 numerical rating scale. Baseline TSBA concentration was correlated with change from baseline (ΔBL) in monthly itch score (MIS). ΔBL in model‐estimated TSBA AUC 0–24 was correlated with time‐matched ΔBL in weekly itch score (WIS) or MIS.
Results
Linerixibat dose dependently reduced TSBA AUC 0–24 , reaching steady state after 5 days. Baseline TSBA levels in GLIMMER did not correlate with ΔBL in MIS. ΔBL in TSBA AUC 0–24 correlated with improved WIS over 12 weeks of treatment ( r = 0.52, p < 0.0001). Of participants with a ≥30% decrease in TSBA AUC 0–24 , 60% were pruritus responders (≥2‐point improvement in WIS from baseline).
Conclusions
Linerixibat treatment leads to rapid, dose‐dependent TSBA reductions. Baseline TSBA levels do not correlate with on‐treatment pruritus change, suggesting they do not predict linerixibat response. Change in TSBA AUC 0–24 correlates significantly with, and can be predictive of, pruritus improvement in patients with PBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- GSK, Durham, North Carolina, USA.
- GSK, Collegeville, Pennsylvania, USA.
- GSK, London, UK.
- Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
ORCID-Profile: Brandon Swift, Janelle Lennie, Andreas E Kremer
Förderung
- GSK
Zitieren
APA
Karatza, E., Swift, B., Carreño, F., Mukherjee, S., Casillas, L., Lennie, J., Fettiplace, J., McLaughlin, M. M., & Kremer, A. E. (2024). Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat. Liver International. https://doi.org/10.1111/liv.15982
Vancouver
Karatza E, Swift B, Carreño F, Mukherjee S, Casillas L, Lennie J, et al. Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat. Liver International. 2024. doi:10.1111/liv.15982
BibTeX
@article{Karatza2024,
author = {Karatza, Eleni and Swift, Brandon and Carreño, Fernando and Mukherjee, Sumanta and Casillas, Linda and Lennie, Janelle and Fettiplace, James and McLaughlin, Megan M and Kremer, Andreas E},
title = {Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15982}
}
EUVIMED